NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

SciSparc Ltd. (SPRC) Stock Analysis

SciSparc Ltd. (SPRC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SPRC

$1.34

+$0.01 (+0.75%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SPRC with… →

SPRC Key Statistics

As of Oct 21, 2026
Trading
Open
$1.34
Previous Close
$1.33
Day's Range
1.31–1.36
52-Week Range
1.21–37.90
Volume
51.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.55
Valuation
Market Cap
$778.50K
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.15
Financials (FY)
Revenue (FY)
$856.00K−34.46%
Net Income (FY)
−$12.18M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
580.97K
1-Year Return
−96.50%
Dividend and dates
Avg Volume
729.21K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SPRC closed at $1.34, −96.50% over 1 year.

SciSparc Ltd. (SPRC) has a market capitalization of $778.50K.

In fiscal 2025, SPRC reported revenue of $856.00K.

SPRC Stock Return by Calendar Year

SciSparc Ltd. (SPRC) return since Aug 2021: what $10,000 became

1 year
$10,000 $350
−96.50%
5 years
$10,000 $0.46
−99.995%
Since Aug 2021
$10,000 $0.61
−99.99%

If you had invested $10,000 in SciSparc Ltd. (SPRC) at the close on August 30, 2021, the earliest close on record here, it would have been worth $0.61 at the close on October 21, 2026: −99.99% in total, −84.87% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−89.05%
2025−82.01%
2024−92.62%
2023−75.17%
2022−87.87%
2021 (partial year)+38.44%

As of October 21, 2026.

SPRC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$856.00K−$12.18M−1,422.8%
2024$1.31M−$6.28M−481.2%
2023$2.88M−$5.12M−177.9%
2022$1.35M−$2.59M−192.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$856.00K$631.00K−$8.75M−$12.18M−1,422.8%
2024$1.31M$506.00K−$7.24M−$6.28M−481.2%
2023$2.88M$2.20M−$5.77M−$5.12M−177.9%
2022$1.35M$1.03M−$8.29M−$2.59M−192.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SPRC Valuation vs Biotechnology Median

Median of 608 stocks
MetricSPRCBiotechnology medianvs median
P/S ratio1.1513.300.1x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 19 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values SciSparc Ltd. (SPRC) at $778.50K. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 3.

The 52-week range on file runs from $1.21 to $37.90. SPRC last closed at $1.34 on October 21, 2026. That is +$0.01 (+0.75%) against the previous close. The latest close sits 10.74% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $856.00K. Against the prior fiscal year total of $1.31M, that is a change of −34.46%. The same year closed with a net loss of $12.18M.

Across the 4 fiscal years on file, revenue moves from $1.35M in 2022 to $856.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The price-to-sales ratio is 1.15. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −96.50%. Across 5 years the annualized return works out at −86.42%. The reported beta is 2.55. Daily returns over the trailing 5 years annualize to a volatility of 190.63%.

Growth & Income

No dividend is on file for SPRC.

Across the complete calendar years on file, 2023 returned −75.17% and 2024 returned −92.62%. Of the 4 complete calendar years on file, 0 finished higher. 2026 is still running; the total return is −89.05% year to date.

Peer Comparison

SciSparc Ltd. (SPRC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
SciSparc Ltd. SPRC $778.50K —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About SciSparc Ltd.

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Visit website →